1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

US FDA Allows Compounding Of Hand Sanitizers During Pandemic

 
• By Joanne S. Eglovitch

Agency refrains from enforcing certain FD&C Act requirements against compounders who prepare alcohol-based hand sanitizers during COVID-19 public health emergency.

Women's hands using wash hand sanitizer gel pump dispenser.
US FDA Gives Green Light To Compounded Hand Sanitizers • Source: Shutterstock

The US Food and Drug Administration announced on 14 March it will not enforce certain Food, Drug and Cosmetic Act provisions against compounders who prepare ethyl and isopropyl alcohol-based hand sanitizers to combat a shortage of these products during the COVID-19 crisis.

The agency will cheer on operations that might otherwise get sanctioned for marketing adulterated drugs because at least their products are

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Pharma Predicts Modest Tariff Impact, Depending On What Comes Next

 
• By Jessica Merrill

Drugmakers are not expecting a big financial hit from tariffs for now, but a report commissioned by the industry trade association PhRMA suggests a potentially steep cost for pharma-sector tariffs.